Ocean Biomedical Inc
NASDAQ:OCEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ocean Biomedical Inc
Total Current Liabilities
Ocean Biomedical Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ocean Biomedical Inc
NASDAQ:OCEA
|
Total Current Liabilities
$33.9m
|
CAGR 3-Years
453%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Total Current Liabilities
$13.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Schlumberger NV
NYSE:SLB
|
Total Current Liabilities
$14.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
0%
|
|
|
Halliburton Co
NYSE:HAL
|
Total Current Liabilities
$5.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Total Current Liabilities
$1.7B
|
CAGR 3-Years
49%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Total Current Liabilities
$271.3m
|
CAGR 3-Years
37%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
Ocean Biomedical Inc
Glance View
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in Providence, Rhode Island. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
See Also
What is Ocean Biomedical Inc's Total Current Liabilities?
Total Current Liabilities
33.9m
USD
Based on the financial report for Dec 31, 2024, Ocean Biomedical Inc's Total Current Liabilities amounts to 33.9m USD.
What is Ocean Biomedical Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
453%
Over the last year, the Total Current Liabilities growth was 13%. The average annual Total Current Liabilities growth rates for Ocean Biomedical Inc have been 453% over the past three years .
